The pathogenesis of gastrointestinal tract involvement in SSc is not fully understood. However, gastrointestinal signs and symptoms are very common. Trials to test therapies, with rare exceptions, should be double-blind, randomized trials with either active therapy or placebo as comparators. Trial duration will vary dependent on the anticipated therapy and should usually be 624 weeks long, although some motility trials may need to be 52 weeks. As in any well-controlled trial, inclusion and exclusion criteria should encourage relatively uniform patients with sufficiently active disease to discern response, importantly considering disease duration. Previous therapy, co-morbid conditions, potentially confounding and/or concomitant therapy should be considered. Outcome measures should include both objective/semi-objective and subjective measures, although validated measures are not frequent and design needs to consider using only validated measures. Unvalidated measures can be included to validate them for future use. A full analysis plan should be completed before study commencement, including the method to account for missing data.
Introduction
The gastrointestinal (GI) tract (GIT) is frequently involved in SSc. As such, it is also a source of patient dissatisfaction, not to mention a source of morbidity and increased mortality. Although changing the underlying course of GI involvement so far remains an elusive goal, symptomatic and partly physiological changes can often improve health-related quality of life. Although fully defined recommendations for GIT studies are not yet developed, we consider the description below to represent reasonable, evidence-based and consensus-based Points to Consider, whose aim is to lend some degree of uniformity and comparability to future trials of therapy for SSc GI disease.
The pathogenesis of GI involvement is not well defined, but it is thought to include an early effect on the vasa nervorum of the nerves supplying the GIT [13] . Downstream effects are thought to result in ineffective function and progressive fibrosis of the GI musculature. This, in turn, leads to decreased motility, dysphagia, decreased gastric emptying, bloating, GI pain, bacterial overgrowth, diarrhoea/constipation and faecal incontinence, as well as weight loss and potential malnutrition [47] . This model can help to explain most of the symptoms associated with GI SSc. However, there is another hypothesis, which posits an autoimmune injury. In one study, high-titre antibodies directed against myenteric neurons were detected in 19 of 41 patients with SSc, but not in patients with idiopathic GI dysmotility [8] .
Although valid, responsive measures of GI involvement are available for diseases other than SSc and could be considered, their characteristics in SSc are not known [913] . Valid measures of GI involvement and change in SSc are few (see Tables 13 ). The UCLA Scleroderma Clinical Trial Consortium (SCTC) GIT 2.0 is best validated, while severity is partly validated using the GI visual analog score scale of the Scleroderma HAQ disability index and the Medsger Severity Scale [1417] .
The UCLA SCTC 2.0 includes 34 items and seven multiitem scales (reflux, distension/bloating, diarrhoea, faecal soilage, constipation, emotional well-being and social functioning) and a total GIT score to assess health-related quality of life (HRQOL) and severity of GIT symptoms in SSc. All scales are scored from 0 (better HRQOL) to 3 (worse HRQOL), except the diarrhoea and constipation (range from 0 to 2 and from 0 to 2.5, respectively), and this provides a total GIT severity scale. The GIT 2.0 takes 68 min to complete and has feasibility, reliability (testretest and internal consistency) and validity in multiple studies. Minimally important differences have been estimated for all scales [18, 19] .
The Subjective Global Assessment is an assessment tool that uses aspects of the history (including, weight change, dietary intake, GI symptoms and functionality) and physical examination (including wasting, oedema and ascites) to classify nutritional status.
More objective measures, such as manometry, endoscopy, motility tests and malabsorption tests, are unvalidated or partly validated (see Tables 14) . Some degree of validation of some of these tests could or should be undertaken before starting GI trials or could be done as a secondary part of contemplated GI trials. A list of possible objective measures is contained in Tables 14. During the discussion below, some of these tests will be used as exploratory or even secondary measures but, because they are not yet fully validated, they should not be used as primary measures of response in GI SSc. With these caveats, we recommend the following points to consider for testing therapies for SSc GI disease.
Hypothesis
The hypothesis was to develop evidence-based recommendations for points to consider in conducting clinical trials to improve or stabilize the GIT in SSc. To make the points to consider more comprehensible, the GIT will be divided into the following regions: oesophagus and stomach, small bowel, colon, rectum and anus.
Study design
As outlined in the general points to consider [21] , strong consideration should be given to designing trials to be double-blind, randomized studies vs active control or placebo. If that is not possible, because of the nature of the outcome variable (e.g. endoscopy), single blinding of the patient-related outcomes should be strongly considered.
If background therapy is considered necessary, the nature of the background therapy should be carefully and completely considered and included in the exclusion/inclusion criteria so that potential confounders are taken into account.
Duration
The duration of the trials needs to be considered in the context of the responsiveness of the portion of the GIT being tested. Studies involving the oesophagus or stomach are usually 612 weeks long, those involving the small bowel usually take 1224 weeks, and motility trials usually require 2452 weeks. It is unknown what the usual or best trial durations are when examining the large bowel or rectum/anus. These trial durations, although the ones usually used and based on empirical evidence, need to be considered in the context of the potential efficacy of the therapies used. Early involvement 
Outcome variables
For consideration when testing therapies in the GIT in SSc, Tables 14 can be consulted. Although many, if not most, semi-objective or objective measures used to examine the GIT in SSc are not fully validated in this disease, there are some data supporting the validity of these measures in other GI illnesses. Tables 13 display the validity of the most common measures used, in SSc. As can be seen, several radiographic techniques, endoscopic techniques (accompanied by biopsies) and manometry have been validated to a large degree in those illnesses. The extrapolation of these data to clinical trials in SSc should be done with caution. The GIT Questionnaire 2.0, the HAQ disability index visual analog scale regarding the GIT and the Medsger Severity Scale have probably been sufficiently validated in SSc. The G.I. PROMIS is also partly validated. The GIT Questionnaire 2.0, the HAQ disability index and the Medsger Severity Scale have been tested in large groups of SSc patients, and no ceiling or floor effects were found. However, such effects can certainly occur for any measure, including the above-mentioned ones, so investigators need to be aware of this possibility. Should specific aspects of the GIT be of interest, questionnaires addressing those symptoms and/or signs can be used from other specialties, although (as noted) their validity in SSc has not been tested or shown. Other subjective measure of GERD, constipation, etc. have been used in other diseases. These include, as a few examples, the GERD-HRQOL, Inflammatory Bowel Disability Index, the REFLUX Questionnaire, Gastroparesis Cardinal Symptom Index-Daily Diary and the Irritable Bowel Syndrome Quality of Life Questionnaire [913]. They have not, as far as we know, been widely used or validated in SSc. Their use in SSc GI clinical trials could be part of efforts to validate them in this disease.
It is advisable to use validated, SSc-specific, patientreported outcome measures in combination with objective or semi-objective measures when considering trials in the GIT for SSc because, thus far, regulatory agencies have not accepted an indication using only a patient response outcome. If possible, preliminary or pilot studies validating any of the measures in SSc from Tables 14 should be considered.
Inclusion criteria
The inclusion/exclusion criteria outlined in the general points to consider have been published [21] . Demographics such as age, disease duration and disease subsets need to be documented. All inclusion criteria need to be guided by the specific goals of the study. Sex should be recorded, although it is not a differentiating demographic.
The GIT changes with disease duration, with increasing involvement and increasing fibrosis over time. It would be logical, then, to assume that the responsiveness of the GIT will decrease with time. Perhaps because the measures of response are poor or because the treatments are non-specific, there are no data showing that responsiveness changes with disease duration. Thus, any disease duration seems allowable when testing therapy for the GIT, although defining disease duration (or analysing for the effect of disease duration on response) should be considered. The use of concomitant GI medications should be carefully considered.
Other SSc-associated visceral disease should also be considered because the degree of SSc visceral involvement can confound the results of GI treatment (e.g. renal involvement or cardiac involvement can compromise test medication kinetics).
Overall GI disease severity needs to be considered (e.g. total parental nutrition or the use of a gastric or gastrojejunal feeding tube) because GI disease severity can confound the ability to measure GI response and impair nutrition. In contrast, GI involvement may be so mild that improvement cannot be measured.
Exclusion criteria
Concomitant diseases that might confound the outcome should be considered. These might include, for example: diabetes mellitus, coeliac disease, IBD, irritable bowel Concomitant medications should be carefully considered. These may be excluded, stratified, included as a variable in the analysis or monitored as a response variable. For the upper GIT, these might include antacids, pro-kinetics or use of a gastric pacemaker. For the lower GIT, prokinetics, antibiotics or a rectal pacemaker might require exclusion or taking into account.
Previous therapy for SSC that might alter response should be carefully considered. For example, the medications required to suppress rejection of a heart, lung or renal transplant should be considered or excluded or taken into account.
Analysis
It is important to be able to describe the patient population fully, to consider the number of patients needed for the trial, to consider how to measure response and to consider how to handle inevitable missing data.
At a minimum, the following analyses should be considered.
A patient disposition table should include descriptive analyses by patient groups, including demographics, ancillary disease characteristics, concomitant medications and concomitant diseases as well as baseline values for outcome measurements. Comparisons among the groups to establish baseline uniformity are strongly recommended.
A pre-defined analysis plan for testing the effect of the test medication or therapy is important. Specific analysis should be considered as needed for the objectives and the trial. It is important, however, that a pre-planned analysis plan should be included. As missing data are inevitable, some plan should be considered for dealing with missing data.
Conclusion
These points to consider for GI involvement in clinical trials of SSc point out that trials should be double-blind randomized trials (with very rare exceptions), should usually be of 624 weeks duration, should usually include semi-objective/objective and subjective measures (using validated measures if possible) and should include predefined analyses. 
